SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS SPECIFICALLY BINDING TO BOTULINUM NEUROTOXIN TYPE A, AND METHOD OF USING THEM FOR THERAPY OR EMERGENCY PREVENTION OF INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A Russian patent published in 2022 - IPC C07K16/12 C12N15/13 

FIELD: biotechnology.

SUBSTANCE: group of inventions relates to biotechnology, immunology and microbiology. Disclosed is a single-domain antibody specifically binding to botulinum neurotoxin type A, having protective activity against a lethal dose of botulinum neurotoxin type A and having the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2. Also created is an oligomerized single-domain antibody specifically binding to botulinum neurotoxin type A, having protective activity against a lethal dose of botulinum neurotoxin type A, containing any version of the created single-domain antibody as a monomer unit. In addition, an antibody is created, which is a single-domain antibody modified with a human immunoglobulin G1 Fc fragment, specifically binding to a botulinum neurotoxin type A, having protective activity against a lethal dose of botulinum neurotoxin type A, having a final amino acid sequence SEQ ID NO: 5 or SEQ ID NO: 6. What is developed is a method of therapy and emergency prevention of intoxication caused by botulinum neurotoxin type A, which consists in introduction of any created antibody in an effective amount into a mammalian body.

EFFECT: group of inventions enables to create a single-domain antibody, which has improved pharmacokinetics compared to single-domain antibodies, which effectively binds and neutralizes botulinum neurotoxin type A and can be used for therapy and emergency prevention of intoxication caused by botulinum neurotoxin type A.

4 cl, 12 dwg, 2 tbl, 15 ex